Friday , 21 June 2024

In-Vitro and In-Vivo Studies of Cyclosporine Nanoparticulate for Targeted Drug Delivery

Mallikarjun Vasam*, Raja Sridhar Rao P
Department of Pharmaceutics, Chaitanya College of Pharmacy Education and Research, Hanamkonda, Warangal, Telangana, India.

Targeted delivery of drug leads to increase in bioavilability and prevent toxicity which is associated with conventional preparations. In this cyclosporine is the immunosuppressive drug used in treatment of autoimmune diseases and prevent nephrotoxicity. Solvent evaporation method was used for preparation of Nanoparticles of Eudragit loaded RL100, containing 2% PVA which acts stabilizer. Four formulations were prepared with varying concentrations (F1, F2, F3 and F4) and cumulative percentage drug release was found to be 84.3%, 87.11%, 91.23% and 88.25%.The best formulations was F3 which has a mean particle size of 275nm and 49.88% entrapment efficiency. In-Vivo studies showed that nanoparticles containing drug targets to liver, spleen, lungs and kidneys. Stability studies showed the concentration of the drug was found closet In-Vitro release to initial data. Nanoparticles containing eudragit targeted to various organs are satisfactory and these are stable at 40c.
Keywords: Cyclosporine, Nanoparticles, Eudragit, Solvent evaporation

Scroll To Top